Yusupov Quoted in First for Women

First for Women quoted NYITCOM Assistant Professor Eleanor Yusupov, D.O., in an article about Ozempic alternatives. Yusupov, who is a board-certified obesity medicine physician and diabetes expert, discussed the Ozempic shortage, and how drugs like Tirzepatide, commonly sold under the brand names Mounjaro (FDA-approved for treating diabetes) and Zepbound (FDA-approved for weight loss), may provide other options depending on the patient’s needs.

“Tirzepatide was approved for weight loss in November 2023. It acts on two gut hormones, GLP-1 and GIP [gastric inhibitory peptide] and can result in even greater weight loss than semaglutide,” says Yusupov. She adds that several other GLP-1 agonists on the market, including liraglutide (Saxenda) and dulaglutide (Trulicity), are also available but seem to have taken a backseat due to the more dramatic weight loss results patients gain from semaglutide and tirzepatide.